Perimeter Medical Imaging to Present Pivotal Clinical Trial Results
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF), a company dedicated to enhancing cancer surgery through advanced imaging technology, is preparing to share significant findings from its pivotal clinical trial. This upcoming announcement revolves around their innovative Perimeter B-Series Optical Coherence Tomography (OCT) system, which is integrated with cutting-edge artificial intelligence (AI) technology. Set to be released after the market's closing on an important date, this announcement will notably focus on breast-conserving surgeries.
Details About the Upcoming Conference Call
In conjunction with the trial results presentation, the management of Perimeter will conduct a live webcast and conference call. This will provide a platform for discussing the topline results and their implications for the future of breast cancer surgery. The company invites stakeholders and the public to tune in and gain insights directly from the management team.
Conference Call Information
For those interested in participating, here are the essential details for the conference call:
- Date: Scheduled for a Wednesday in November.
- Time: 5:00 PM Eastern Time.
- Dial-In Numbers: 1-800-717-1738 for callers from Canada and the U.S., and 1-646-307-1865 for international participants.
Introducing the Perimeter B-Series OCT with ImgAssist AI
The Perimeter B-Series OCT represents a significant advancement in imaging technologies designed specifically for breast cancer surgeries. By leveraging proprietary AI technology alongside advanced imaging, the B-Series aims to improve the quality and precision of surgical outcomes. The ongoing pivotal trial is crucial in evaluating its effectiveness in real clinical settings.
About Perimeter Medical Imaging AI
With roots in innovation, Perimeter Medical Imaging AI is committed to transforming cancer surgery using ultra-high-resolution, real-time imaging tools. Their FDA-cleared Perimeter S-Series OCT system illustrates the company’s dedication to providing real-time tissue visualization at the cellular level. The next step, the Perimeter B-Series, is currently undergoing evaluation in a pivotal clinical trial, backed by a substantial grant aimed at advancing cancer research.
Looking Forward: What This Means for the Future
The results from the upcoming trial could significantly influence how breast-conserving surgeries are performed, potentially leading to enhanced patient outcomes and reduced re-excision rates. The integration of AI in the Perimeter B-Series OCT may redefine the standards of care in oncology, offering surgeons the advanced tools necessary to make informed decisions during operations.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to discuss the topline results from Perimeter's pivotal trial evaluating the B-Series OCT system.
What does the Perimeter B-Series OCT do?
The B-Series OCT is designed to provide real-time, high-resolution imaging of breast tissues during surgeries, enhancing surgical precision.
How does Perimeter's technology differ from traditional imaging methods?
Perimeter's technology integrates advanced AI with OCT, allowing for more detailed visualization and analysis of excised tissues compared to conventional methods.
What are the potential benefits of the B-Series OCT?
Potential benefits include improved surgical accuracy, lower rates of re-excision, and overall better outcomes for patients undergoing breast cancer surgery.
How can I learn more about Perimeter Medical Imaging AI?
For more information, visit their company's website to find updates on their technologies, trials, and results.
